MetaADEDB 2.0 @ LMMD
Tri-Luma
(ATTPXNCCXYEULE-JOBJWGHLSA-N)
Structure
SMILES
C/C(=C\C=C\C(=C\C(=O)O)\C)/C=C/C1=C(C)CCCC1(C)C.Oc1ccc(cc1)O.OCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@]2([C@H]1C[C@@H](C1=CC(=O)C=C[C@]21C)F)F)(C)C
Molecular Formula:
C50H64F2O10
Molecular Weight:
863.034
Log P:
9.0672
Hydrogen Bond Acceptor:
10
Hydrogen Bond Donor:
5
TPSA:
170.82
CAS Number(s):
940291-89-4
Synonym(s)
1.
Tri-Luma
External Link(s)
PubChem Compound24848068
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1ErythemaFAERS: 48US FAERS
2Drug ineffectiveFAERS: 26US FAERS
3Skin irritationFAERS: 19US FAERS
4Product use issueFAERS: 15US FAERS
5Incorrect product storageFAERS: 14US FAERS
6Product use in unapproved indicationFAERS: 13US FAERS
7Intentional product use issueFAERS: 10US FAERS
8PruritusFAERS: 10US FAERS
9Drug ineffective for unapproved indicationFAERS: 9US FAERS
10Inappropriate schedule of drug administrationFAERS: 7US FAERS
11HypersensitivityFAERS: 6US FAERS
12Intentional product misuseFAERS: 6US FAERS
13DermatitisFAERS: 4US FAERS
14Dry skinFAERS: 4US FAERS
15Accidental exposureFAERS: 3US FAERS
16ChloasmaFAERS: 3US FAERS
17Emotional distressFAERS: 3US FAERS
18Eye BurnsFAERS: 3US FAERS
19Eye irritationFAERS: 3US FAERS
20Eye painFAERS: 3US FAERS
21Inappropriate schedule of product administrationFAERS: 3US FAERS
22Incorrect drug administration durationFAERS: 3US FAERS
23Product storage errorFAERS: 3US FAERS
24Application site erythemaFAERS: 2US FAERS
25Burning sensationFAERS: 2US FAERS
26Medication residueFAERS: 2US FAERS
27Medication residue presentFAERS: 2US FAERS
28Pain of skinFAERS: 2US FAERS
29PapuleFAERS: 2US FAERS
30Rash erythematousFAERS: 2US FAERS
31Rebound effectFAERS: 2US FAERS
32ScabFAERS: 2US FAERS
33Visual disturbanceFAERS: 2US FAERS
34AcneFAERS: 1US FAERS
35Application site exfoliationFAERS: 1US FAERS
36Application site painFAERS: 1US FAERS
37Application site urticariaFAERS: 1US FAERS
38CheilitisFAERS: 1US FAERS
39CryingFAERS: 1US FAERS
40DeformityFAERS: 1US FAERS
41Depressed moodFAERS: 1US FAERS
42DizzinessFAERS: 1US FAERS
43Drug administered at inappropriate siteFAERS: 1US FAERS
44Drug administration errorFAERS: 1US FAERS
45Expired drug administeredFAERS: 1US FAERS
46Expired product administeredFAERS: 1US FAERS
47HeadacheFAERS: 1US FAERS
48KeratitisFAERS: 1US FAERS
49Lip exfoliationFAERS: 1US FAERS
50NervousnessFAERS: 1US FAERS
51Optic NeuritisFAERS: 1US FAERS
52Paradoxical drug reactionFAERS: 1US FAERS
53Patient dissatisfaction with treatmentFAERS: 1US FAERS
54PhotophobiaFAERS: 1US FAERS
55Poor quality product administeredFAERS: 1US FAERS
56Post inflammatory pigmentation changeFAERS: 1US FAERS
57Product adhesion issueFAERS: 1US FAERS
58Product physical consistency issueFAERS: 1US FAERS
59Product physical issueFAERS: 1US FAERS
60Product quality issueFAERS: 1US FAERS
61Skin UlcerFAERS: 1US FAERS
62Skin discomfortFAERS: 1US FAERS
63Skin hypertrophyFAERS: 1US FAERS
64Skin reactionFAERS: 1US FAERS
65StrabismusFAERS: 1US FAERS
66SwellingFAERS: 1US FAERS
67UrticariaFAERS: 1US FAERS
68skin abrasionFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120269

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.